Biologics for asthma and risk of pneumonia-Reference-Cited by-同舟云学术

Biologics for asthma and risk of pneumonia

Published:2024-02-07 Issue:9 Volume:61 Page:905-911
ISSN:0277-0903
Container-title:Journal of Asthma
language:en
Short-container-title:Journal of Asthma

Author:

Matera Maria Gabriella¹,Ora Josuel²,Calzetta Luigino³,Rogliani Paola²⁴,Cazzola Mario⁴^ORCID

Affiliation:

1. Unit of Pharmacology, Department of Experimental Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy

2. Division of Respiratory Medicine, University Hospital “Fondazione Policlinico Tor Vergata”, Rome, Italy

3. Respiratory Disease and Lung Function Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy

4. Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome “Tor Vergata”, Rome, Italy

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/02770903.2024.2311236

Reference43 articles.

1. Revisiting asthma pharmacotherapy: where do we stand and where do we want to go?

2. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Introduction)

3. Biologics for Asthma and Risk of Infection

4. The risk of respiratory tract infections and antibiotic use in a general population and among people with asthma

5. U.S. Food and Drug Administration. FDA Adverse Event Reporting System (FAERS) public dashboard. Available from: https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Severe hypereosinophilia in a patient treated with dupilumab and shift to mepolizumab: the importance of multidisciplinary management. A case report and literature review;Drugs in Context;2024-05-22